The Stress Responses of Fetuses and Infants Whose Mothers Smoked During Pregnancy
NCT ID: NCT00563966
Last Updated: 2008-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2008-04-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We hypothesize that the risk imposed on infants by antenatal exposure to nicotine is moderated by genotype that influences functioning of the HPA axis, metabolism of nicotine, and stress-levels and parenting that influence the development of neural substrates (HPA axis) and infants' capacity to cope with stress. There is a growing consensus that Gene x Environmental (G x E) interplay likely mediated by epigenetic effects constitute one of the central mechanism by which complex disorders develop. Our proposal offers an exceptional paradigm to explore the association between genes, environment, and G x E interactions on the neural and behavior response of children to stressful challenges.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Design overview. A large cohort of pregnant women will be recruited, and those who meet criteria will be divided into two groups according to their testimony regarding their smoking behavior and saliva cotinine screening, as in our previous studies. At 3-time points, the antenatal period, 2-days and 6-months of age; we will assess infants' responses to challenges using biochemical, behavioral, and subjective measures. The challenges selected are "proven" stressors and previous research has demonstrated their effectiveness in eliciting stress-reactions (e.g., increased cortisol). In parallel, we will obtain an obstetric history (from medical records), demographics, measure of symptomology, information on smoking and drinking habits, life stresses, and family cohesion at each time point, plus information about mothers' feelings/behavior and mothers' ratings of infants "regulatory" behavior after birth. The antenatal and neonatal sessions will be carried out in Hadassah Hospital and the 6-month session in the developmental laboratory at Hebrew University. Genetic material will be collected from parents and their infant at childbirth.
Recruitment Women smokers will be recruited will be recruited by nurses in well-baby clinics (where physicians do routine prenatal check-ups), gynecologists, midwives, and by advertisement. In addition, we will recruit women at the time of routine checks in Hadassah hospital (Nuchal translucency test) at 12 weeks, triple/quadra test blood testing at 16 weeks, early (14-16 weeks) and advanced (20-22 week) fetal anatomy scan, and glucose test at 24-28 weeks) (supervised by Dr. Mankuta). In all, we will recruit 150 women for the "smoking" group, using the following inclusion criteria: smokes at least 10 cigarettes a day (i.e., habitual smokers) no abuse of alcohol or drugs, no chronic physical disability, 22-35 years of age, living with partner, speaks English, Hebrew, or Russian, natural conception). A (second) group of 150 women who meet inclusion criteria (except smoking) and matched in age, education, gender of infant, and parity to the "smokers" will serve as controls. At recruitment and each time-point, mothers (and their spouses) who agree to participate in the research protocol will be interviewed for smoking habits (Fagerstrom Tolerance Questionnaire, FTQ) as detailed in our previous studies on smoking. At recruitment, women will be explicitly told that we are not encouraging smoking and will provide resources if, at any time, during the study, they want to stop smoking.
Antenatal period (Dr. David Mankuta)
The prenatal session will be carried out at 34-36 weeks of gestation (by last menstrual period and confirmed by early ultrasound) and will consist of 3 phases: (1) waiting room- in which mothers receive instructions, (2) ultrasound- to evaluate limb movement before and after vibroacoustic stimulation (VAS), as well as measures of fetuses' well-being (cardiotocograph test, biophysical profile), and (3) post exam- administration of questionnaires.
Limb movement. Measures of fetal limb movement are good reflections of infant state, are stable from late gestation out to 4-weeks postnatal age 80 , are affected by antenatal stress 81, and forecast infants' state regulation 2 weeks after birth. Ultrasound (ATL 3500 and 5000) will be used to visualize and film the fetus for offline coding of limb movements. To begin testing, infant must be in state 1F, characterized by minimal fetal movement for 2 minutes. When this criterion is met, baseline the VAS (Fetal Acoustic Corometrics Stimulator Model 146; ≈75 HZ, ≈82 db) will be presented for 5 s. Fetal movements will be videotaped with the recorder built into the scanner. During off-line time-event coding, each limb movement will be counted. From these raw counts, we will average the number of movements observed in 10 s intervals during the 1 min prior to (baseline) and during the 5 min after stimulation. Reactivity will be derived by calculating the difference between the mean baseline count and the mean count recorded during the 5 s of stimulation. Regulation will be calculated as (1) the slope of the counts across the post stimulation period (5 minutes), and (2) the difference between the mean baseline count and the mean count of last three 10 second epochs. for first time point. Previous studies have shown limb-counts to be stable (24-36 weeks), reliable, and sensitive to maternal stress.
Questionnaires
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
FAMILY_BASED
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No abuse of alcohol or drugs
* No chronic physical disability
* 22-35 years of age
* Living with partner
* Speaks English, Hebrew, or Russian
* Natural conception
22 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hebrew University of Jerusalem
OTHER
Hadassah Medical Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hadassah
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ebstein Richard, MD PhD
Role: STUDY_CHAIR
Hebrew University Jerusalem Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah Medical Organization
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
David Mankuta, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
smokingmothers-HMO-CTIL
Identifier Type: -
Identifier Source: org_study_id